Table 1.
Duration of severe ventricular arrhythmias during reperfusion.
| Experimental Groups | Ventricular Tachycardia | Ventricular Fibrillation |
|---|---|---|
| Control | 45.0 (10–142) | 476.0 (198–555) |
| IPoC | 17.0 (3–146) | 5.0 (0–115) ** |
| CPT | 11.0 (0–41) | 459.0 (228–555) |
| IPoC + CPT | 68.0 (28–235) | 250.5 (121–291) |
| DMSO | 45.0 (24–123) | 529.0 (205–582) |
| IPoCd | 27.5 (3–146) | 10.5 (0–141) ** |
| SCH | 50.5 (33–110) | 398.5 (124–460) |
| IPoC + SCH | 64.0 (25–128) | 282.0 (112–505) |
| MRS | 35.0 (8–99) | 520.0 (233–563) |
| IPoC + MRS | 82.5 (20–186) | 263.0 (0–415) |
| CHE | 41.0 (20–51) | 467.5 (295–545) |
| IPoC + CHE | 71.5 (38–133) | 360.0 (224–460) |
| GLI | 401.0 (260–542) ** | 61.5 (18–75) * |
| IPoC + GLI | 33.5 (12–63) | 66.0 (12–90) * |
| ADOi10 | 141.0 (60–242) | 91.5 (30–135) * |
| ADOi100 | 120.5 (22–195) | 66.5 (0–106) * |
| GIPoC | 39.5 (18–87) | 48.0 (0–78) ** |
Values are expressed in seconds and correspond to median (interquartile range). Cyclopentyl theophylline (CPT), adenosine A1 receptor antagonist; dimethyl sulfoxide (DMSO), vehicle of the drugs; vehicle perfusion during IPoC procedure (IPoCd); SCH 58261(SCH), adenosine A2A receptor antagonist; MRS-1523 (MRS), adenosine A3 receptor antagonist; chelerythrine (CHE), non-selective PKC inhibitor; glibenclamide (GLI), non-selective KATP channels inhibitor; adenosine intermittent (ADOi) during reperfusion; intermittent global myocardial ischemia as postconditioning stimuli (GIPoC). * p < 0.05 and ** p < 0.01 vs. control by Kruskal-Wallis.